Labeling of Red Blood Cell Units With Historical Antigen Typing Results; Guidance for Industry; Availability, 65689-65690 [2018-27654]

Download as PDF Federal Register / Vol. 83, No. 245 / Friday, December 21, 2018 / Notices Rockville, MD: U.S. Department of Health and Human Services, SAMHSA, Center for Behavioral Health Statistics and Quality; 2017. 6. Noar, S.M., Hall, M.G., Francis, D.B., et al. ‘‘Pictorial Cigarette Pack Warnings: A Meta-Analysis of Experimental Studies’’. Tobacco Control, 25:341–354, 2016. Dated: December 18, 2018. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2018–27658 Filed 12–20–18; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2016–D–4308] Labeling of Red Blood Cell Units With Historical Antigen Typing Results; Guidance for Industry; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled ‘‘Labeling of Red Blood Cell Units with Historical Antigen Typing Results; Guidance for Industry.’’ The guidance document provides establishments that collect blood and blood components for transfusion with recommendations for labeling Red Blood Cell (RBC) units with non-ABO/Rh(D) antigen typing results obtained from previous donations (historical antigen typing results). The guidance provides recommendations to transfusion services for managing RBC units labeled with historical antigen typing results. The guidance also provides licensed blood establishments that choose to implement labeling of RBC units with historical antigen typing results instructions regarding how to report the manufacturing and labeling changes under the biologics regulations. The guidance does not apply to test results for ABO and Rh(D) antigens. The guidance announced in this notice finalizes the draft guidance of the same title dated January 2017. amozie on DSK3GDR082PROD with NOTICES1 SUMMARY: The announcement of the guidance is published in the Federal Register on December 21, 2018. DATES: You may submit either electronic or written comments on Agency guidances at any time as follows: ADDRESSES: VerDate Sep<11>2014 00:00 Dec 21, 2018 Jkt 247001 65689 with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS Submit electronic comments in the CONFIDENTIAL INFORMATION.’’ The following way: • Federal eRulemaking Portal: https:// Agency will review this copy, including the claimed confidential information, in www.regulations.gov. Follow the its consideration of comments. The instructions for submitting comments. second copy, which will have the Comments submitted electronically, claimed confidential information including attachments, to https:// redacted/blacked out, will be available www.regulations.gov will be posted to for public viewing and posted on the docket unchanged. Because your https://www.regulations.gov. Submit comment will be made public, you are both copies to the Dockets Management solely responsible for ensuring that your Staff. If you do not wish your name and comment does not include any contact information to be made publicly confidential information that you or a available, you can provide this third party may not wish to be posted, information on the cover sheet and not such as medical information, your or anyone else’s Social Security number, or in the body of your comments and you confidential business information, such must identify this information as ‘‘confidential.’’ Any information marked as a manufacturing process. Please note as ‘‘confidential’’ will not be disclosed that if you include your name, contact except in accordance with 21 CFR 10.20 information, or other information that and other applicable disclosure law. For identifies you in the body of your more information about FDA’s posting comments, that information will be of comments to public dockets, see 80 posted on https://www.regulations.gov. FR 56469, September 18, 2015, or access • If you want to submit a comment the information at: https://www.gpo.gov/ with confidential information that you fdsys/pkg/FR-2015-09-18/pdf/2015do not wish to be made available to the 23389.pdf. public, submit the comment as a Docket: For access to the docket to written/paper submission and in the read background documents or the manner detailed (see ‘‘Written/Paper electronic and written/paper comments Submissions’’ and ‘‘Instructions’’). received, go to https:// Written/Paper Submissions www.regulations.gov and insert the Submit written/paper submissions as docket number, found in brackets in the follows: heading of this document, into the • Mail/Hand delivery/Courier (for ‘‘Search’’ box and follow the prompts written/paper submissions): Dockets and/or go to the Dockets Management Management Staff (HFA–305), Food and Staff, 5630 Fishers Lane, Rm. 1061, Drug Administration, 5630 Fishers Rockville, MD 20852. Lane, Rm. 1061, Rockville, MD 20852. You may submit comments on any • For written/paper comments guidance at any time (see 21 CFR submitted to the Dockets Management 10.115(g)(5)). Staff, FDA will post your comment, as Submit written requests for single well as any attachments, except for copies of the guidance to the Office of information submitted, marked and Communication, Outreach and identified, as confidential, if submitted Development, Center for Biologics as detailed in ‘‘Instructions.’’ Instructions: All submissions received Evaluation and Research (CBER), Food must include the Docket No. FDA 2016– and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 3128, D–4308 for ‘‘Labeling of Red Blood Cell Silver Spring, MD 20993–0002. Send Units with Historical Antigen Typing one self-addressed adhesive label to Results; Guidance for Industry.’’ assist the office in processing your Received comments will be placed in requests. The guidance may also be the docket and, except for those obtained by mail by calling CBER at 1– submitted as ‘‘Confidential 800–835–4709 or 240–402–8010. See Submissions,’’ publicly viewable at the SUPPLEMENTARY INFORMATION section https://www.regulations.gov or at the for electronic access to the guidance Dockets Management Staff between 9 document. a.m. and 4 p.m., Monday through Friday. FOR FURTHER INFORMATION CONTACT: • Confidential Submissions—To Melissa Segal, Center for Biologics submit a comment with confidential Evaluation and Research, Food and information that you do not wish to be Drug Administration, 10903 New made publicly available, submit your Hampshire Ave., Bldg. 71, Rm. 7301, comments only as a written/paper Silver Spring, MD 20993–0002, 240– submission. You should submit two 402–7911. copies total. One copy will include the information you claim to be confidential SUPPLEMENTARY INFORMATION: Electronic Submissions PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 E:\FR\FM\21DEN1.SGM 21DEN1 amozie on DSK3GDR082PROD with NOTICES1 65690 Federal Register / Vol. 83, No. 245 / Friday, December 21, 2018 / Notices I. Background FDA is announcing the availability of a document entitled ‘‘Labeling of Red Blood Cell Units with Historical Antigen Typing Results; Guidance for Industry.’’ The guidance document provides establishments that collect blood and blood components for transfusion with recommendations for labeling RBC units with historical antigen typing results. The guidance provides recommendations to transfusion services for managing RBC units labeled with historical antigen typing results. This guidance also provides licensed blood establishments that choose to implement labeling of RBC units with historical antigen typing results instructions regarding how to report the manufacturing and labeling changes under 21 CFR 601.12. The guidance does not apply to test results for ABO and Rh(D) antigens. For ABO and Rh(D) antigens, establishments must follow FDA requirements in 21 CFR 640.5(b) and (c), and 606.121(c)(9) and (13), as well as all other applicable requirements. FDA’s Blood Products Advisory Committee discussed this topic on December 4, 2012, and supported the concept of using historical RBC antigen typing results to label RBC units. AABB has revised its standards to include accommodations for labeling RBC units with historical RBC typing results. According to the 30th edition of the AABB Standards for Blood Banks and Transfusion Services, RBC units may be labeled as RBC antigen negative without testing the current donation if two previous separate donations were tested by the collection facility and results of RBC typing were found to be concordant. The standards indicate that facilities have the option to put the nonABO/Rh(D) historical antigen typing results on a tie-tag or directly on the container label. In the Federal Register of January 3, 2017 (82 FR 130), FDA announced the availability of the draft guidance of the same title dated January 2017. FDA received several comments on the draft guidance and those comments were considered as the guidance was finalized. In addition, editorial changes were made to improve clarity. The guidance announced in this notice finalizes the draft guidance dated January 2017. This guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The guidance represents the current thinking of FDA on labeling of red blood cell units with historical antigen typing results. It does not establish any rights VerDate Sep<11>2014 00:00 Dec 21, 2018 Jkt 247001 for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. This guidance is not subject to Executive Order 12866. II. Paperwork Reduction Act of 1995 This guidance contains information collection provisions that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501– 3520). The guidance refers to the collections of information for putting the non-ABO/Rh(D) historical antigen typing results on a tie-tag or directly on the container label. These collections of information have been approved under OMB control number 0910–0862. The guidance also refers to previously approved collections of information found in FDA regulations. The collections of information in 21 CFR part 601 and Form FDA 356h have been approved under OMB control number 0910–0338; and the collections of information in 21 CFR part 606 have been approved under OMB control number 0910-0116. being developed under the 21st Century Cures Act (Cures Act), which directs FDA to issue guidance on how a person seeking to develop and submit a proposed draft guidance relating to patient experience data for consideration by FDA may submit such proposed draft guidance to the Agency. DATES: Submit either electronic or written comments on the draft guidance by March 21, 2019 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. ADDRESSES: You may submit comments on any guidance at any time as follows Electronic Submissions DEPARTMENT OF HEALTH AND HUMAN SERVICES Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Food and Drug Administration Written/Paper Submissions [Docket No. FDA–2018–D–4455] Submit written/paper submissions as follows: • Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2018–D–4455 for ‘‘Developing and Submitting Proposed Draft Guidance III. Electronic Access Persons with access to the internet may obtain the guidance at either https://www.fda.gov/BiologicsBlood Vaccines/Guidance ComplianceRegulatoryInformation/ Guidances/default.htm or https:// www.regulations.gov. Dated: December 18, 2018. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2018–27654 Filed 12–20–18; 8:45 am] BILLING CODE 4164–01–P Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data; Draft Guidance for Industry and Other Stakeholders; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ‘‘Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data.’’ This draft guidance is SUMMARY: PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 E:\FR\FM\21DEN1.SGM 21DEN1

Agencies

[Federal Register Volume 83, Number 245 (Friday, December 21, 2018)]
[Notices]
[Pages 65689-65690]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-27654]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-D-4308]

Labeling of Red Blood Cell Units With Historical Antigen Typing
Results; Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a final guidance entitled ``Labeling of Red Blood
Cell Units with Historical Antigen Typing Results; Guidance for
Industry.'' The guidance document provides establishments that collect
blood and blood components for transfusion with recommendations for
labeling Red Blood Cell (RBC) units with non-ABO/Rh(D) antigen typing
results obtained from previous donations (historical antigen typing
results). The guidance provides recommendations to transfusion services
for managing RBC units labeled with historical antigen typing results.
The guidance also provides licensed blood establishments that choose to
implement labeling of RBC units with historical antigen typing results
instructions regarding how to report the manufacturing and labeling
changes under the biologics regulations. The guidance does not apply to
test results for ABO and Rh(D) antigens. The guidance announced in this
notice finalizes the draft guidance of the same title dated January
2017.

DATES: The announcement of the guidance is published in the Federal
Register on December 21, 2018.

ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA 2016-D-4308 for ``Labeling of Red Blood Cell Units with Historical
Antigen Typing Results; Guidance for Industry.'' Received comments will
be placed in the docket and, except for those submitted as
``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single copies of the guidance to the
Office of Communication, Outreach and Development, Center for Biologics
Evaluation and Research (CBER), Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist the office in processing
your requests. The guidance may also be obtained by mail by calling
CBER at 1-800-835-4709 or 240-402-8010. See the SUPPLEMENTARY
INFORMATION section for electronic access to the guidance document.

FOR FURTHER INFORMATION CONTACT: Melissa Segal, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-
402-7911.

SUPPLEMENTARY INFORMATION:

[[Page 65690]]

I. Background

FDA is announcing the availability of a document entitled
``Labeling of Red Blood Cell Units with Historical Antigen Typing
Results; Guidance for Industry.'' The guidance document provides
establishments that collect blood and blood components for transfusion
with recommendations for labeling RBC units with historical antigen
typing results. The guidance provides recommendations to transfusion
services for managing RBC units labeled with historical antigen typing
results. This guidance also provides licensed blood establishments that
choose to implement labeling of RBC units with historical antigen
typing results instructions regarding how to report the manufacturing
and labeling changes under 21 CFR 601.12. The guidance does not apply
to test results for ABO and Rh(D) antigens. For ABO and Rh(D) antigens,
establishments must follow FDA requirements in 21 CFR 640.5(b) and (c),
and 606.121(c)(9) and (13), as well as all other applicable
requirements.
FDA's Blood Products Advisory Committee discussed this topic on
December 4, 2012, and supported the concept of using historical RBC
antigen typing results to label RBC units. AABB has revised its
standards to include accommodations for labeling RBC units with
historical RBC typing results. According to the 30th edition of the
AABB Standards for Blood Banks and Transfusion Services, RBC units may
be labeled as RBC antigen negative without testing the current donation
if two previous separate donations were tested by the collection
facility and results of RBC typing were found to be concordant. The
standards indicate that facilities have the option to put the non-ABO/
Rh(D) historical antigen typing results on a tie-tag or directly on the
container label.
In the Federal Register of January 3, 2017 (82 FR 130), FDA
announced the availability of the draft guidance of the same title
dated January 2017. FDA received several comments on the draft guidance
and those comments were considered as the guidance was finalized. In
addition, editorial changes were made to improve clarity. The guidance
announced in this notice finalizes the draft guidance dated January
2017.
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
current thinking of FDA on labeling of red blood cell units with
historical antigen typing results. It does not establish any rights for
any person and is not binding on FDA or the public. You can use an
alternative approach if it satisfies the requirements of the applicable
statutes and regulations. This guidance is not subject to Executive
Order 12866.

II. Paperwork Reduction Act of 1995

This guidance contains information collection provisions that are
subject to review by the Office of Management and Budget (OMB) under
the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The guidance
refers to the collections of information for putting the non-ABO/Rh(D)
historical antigen typing results on a tie-tag or directly on the
container label. These collections of information have been approved
under OMB control number 0910-0862. The guidance also refers to
previously approved collections of information found in FDA
regulations. The collections of information in 21 CFR part 601 and Form
FDA 356h have been approved under OMB control number 0910-0338; and the
collections of information in 21 CFR part 606 have been approved under
OMB control number 0910-0116.

III. Electronic Access

Persons with access to the internet may obtain the guidance at
either https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or
https://www.regulations.gov.

Dated: December 18, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-27654 Filed 12-20-18; 8:45 am]
BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.